Optic Pathway (Optic Nerve) Glioma Imaging and Diagnosis
Updated: Aug 26, 2020
Author: Richard J Woodcock, Jr, MD; Chief Editor: L Gill Naul, MD
Practice Essentials
Optic nerve glioma (also known as optic pathway glioma) is the most common primary neoplasm of the optic nerve. Optic pathway gliomas are benign tumors that are classified as pilocytic astrocytomas. They constitute 50% of primary optic nerve tumors and 1.5-4% of all orbital tumors.[1, 2] Along with reducing visual acuity in the affected eye, the tumor sometimes produces additional symptoms as it grows. A low-grade form of this neoplasm, benign optic glioma, occurs most often in pediatric patients. Another form, aggressive glioma, is most common in adults; it is frequently fatal, even with treatment.[3, 4, 5] Many children with optic nerve glioma are also known to have neurofibromatosis type 1 (NF-1) or, in some cases, hybrid phakomatosis.[6, 7, 8]
(See the images below.)
Coronal noncontrast T1-weighted MRI reveals a large intraorbital mass (arrow) centered on the optic nerve.
Axial T2-weighted MRI in a 46-year-old man demonstrates a mass in the lateral geniculate nucleus of the thalamus resulting from contiguous extension of the patient's known optic nerve glioma.
Preferred examination
Contrasted computed tomography (CT) scanning can be used to characterize local involvement of optic nerve glioma within the orbit. However, magnetic resonance imaging (MRI) better demonstrates the extent of the lesion's intracranial growth.[9, 10] Although MRI may reveal even subtle lesions of the optic nerve, CT scanning can detect a subtle erosion or expansion of the optic canal. In addition, fine calcification, which may help to identify a lesion as a meningioma rather than a glioma, is visualized best through CT scanning.
When the diagnosis is in question, the presence of an intraconal mass can often be detected through CT scanning. MRI, however, is the preferred method for definitive evaluation of optic nerve glioma. Both the intraorbital lesion and its intracranial extent can be effectively characterized through MRI. When evaluating the orbit, gadolinium-enhanced T1-weighted images with fat saturation can define the extent of aggressive glioma. Intracranially, MRI allows better evaluation of the optic nerve, chiasm, tracts, geniculate body, and optic radiations than does CT.[4, 5, 11, 12, 13, 14, 15, 16, 17]
Gadolinium-based contrast agents have been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MRA scans. NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness. For more information, see Use of Gadolinium in MRI and MRA Linked to NSF/NFD in Patients With Renal Failure.
Computed Tomography
In children, unenhanced CT scans typically reveal a marked, diffuse enlargement of the optic nerve, with characteristic kinking or bending. The enlargement may be tubular, fusiform, or excrescent.[18] Areas of lucency may result from mucinous or cystic changes. Approximately 50% of the lesions demonstrate enhancement; this characteristic is more common with intracranial (especially retrochiasmatic) extension. Calcifications are rare.
The diagnosis may be made with a high degree of confidence when the lesion involves the optic chiasm and retrochiasmatic optic pathway. When confined exclusively to the orbit, the lesion may mimic optic neuritis or optic nerve meningioma; in this setting and in most instances, MRI is a better diagnostic tool than is CT scanning. CT scanning is the better modality for identifying uncommon meningioma with flecks of calcification, which are rare in optic nerve glioma.
False-positive results can occur because of unilateral optic nerve enhancement or other unilateral disorders, such as optic meningioma, vascular lesions, neuritis, pseudotumor, and sarcoidosis. In addition, subtle nerve enhancement occasionally may develop in normal individuals. Improper examination techniques, including failure to administer contrast or obtain thin sections, can lead to a false-negative diagnosis.
Magnetic Resonance Imaging
The diagnosis may be made with a high degree of confidence on MRI when the lesion involves the optic chiasm and retrochiasmatic optic pathway. When confined exclusively to the orbit, the lesion may mimic optic neuritis, pseudotumor, lymphoma, or optic nerve meningioma. Classically, meningioma, the primary differential diagnostic consideration, is characterized by the "tram-track" sign,[19] with enhancement of the periphery of the nerve–optic sheath unit. On the other hand, enhancement in optic nerve glioma is more uniform. Isolated enlargement of the optic nerve sheath also may present diagnostic difficulty; however, this enlargement can usually be distinguished by its signal characteristics, which follow fluid signal on all MRI pulse sequences.
In most instances, including those described above, the diagnosis can be made with greater confidence using MRI than it can with CT scanning. A false-positive diagnosis can occur as a result of unilateral optic nerve enhancement or other unilateral disorders, such as optic meningioma, vascular lesions, neuritis, pseudotumor, lymphoma, and sarcoidosis. In addition, subtle nerve enhancement occasionally may develop in normal individuals. Improper examination techniques, including failure to administer contrast, use fat saturation, or obtain thin sections, can result in a false-negative diagnosis.
Usually, the lesions are hypointense to isointense relative to the optic nerve on T1-weighted images and are hyperintense to it on T2-weighted images. Enhancement is uniform and intense.
Patients without NF-1 demonstrate cystic components more commonly at T2 -weighted imaging.[20]
On T1-weighted images, optic nerve gliomas are usually isointense to the cortex and hypointense to white matter. Invariably, the lesions are hypointense to orbital fat.[5, 17]
(See the image below.)
Coronal noncontrast T1-weighted MRI reveals a large intraorbital mass (arrow) centered on the optic nerve.
On T2-weighted images, lesions demonstrate a mixed appearance that is isointense to hyperintense relative to white matter and the cortex. Following contrast administration, intense enhancement is common. (See the images below.)
Coronal postgadolinium T1-weighted MRI with fat saturation reveals diffuse, intense enhancement of the intraorbital mass (arrow).
Axial postgadolinium T1-weighted MRI with fat saturation reveals diffuse, intense enhancement of the intraorbital mass. The lesion is confined to the orbit.
Axial postgadolinium T1-weighted MRI with fat saturation in a 6-year-old girl demonstrates enhancement of the intracranial optic nerve (arrow), which is slightly expanded.
A diagnosis of NF-1 may be supported by several findings including the following:
-
Bilateral optic nerve gliomas (see the image below)
Axial noncontrast T1-weighted MRI reveals bilateral, fusiform enlargement of the optic nerves (arrows) in a 14-year-old patient with neurofibromatosis type 1, consistent with bilateral optic nerve gliomas.
-
Spongiform changes (hyperintensity on T2-weighted images) in the cerebellum, brain stem, basal ganglia, thalamus, periventricular white matter, and corpus callosum
Adult lesions may involve the orbital, intracanalicular, or prechiasmal portions of the optic nerve, resulting in enlargement; they may exhibit retrochiasmatic extension as well. (See the images below.)
Axial noncontrast T1-weighted MRI in a 46-year-old man demonstrates enlargement of both optic tracts (arrowheads) and the optic chiasm (arrow).
Axial T2-weighted MRI in a 46-year-old man demonstrates a mass in the lateral geniculate nucleus of the thalamus resulting from contiguous extension of the patient's known optic nerve glioma.
Author
Richard J Woodcock, Jr, MD Consulting Radiologist, Atlanta Radiology Consultants, LLC; Consulting Radiologist and MRI Director, St Joseph's Hospital
Richard J Woodcock, Jr, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Radiology, Phi Beta Kappa, American Medical Association, American Roentgen Ray Society, American Society of Neuroradiology, Radiological Society of North America
Disclosure: Nothing to disclose.
Specialty Editor Board
Bernard D Coombs, MB, ChB, PhD Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.
C Douglas Phillips, MD, FACR Director of Head and Neck Imaging, Division of Neuroradiology, New York-Presbyterian Hospital; Professor of Radiology, Weill Cornell Medical College
C Douglas Phillips, MD, FACR is a member of the following medical societies: American College of Radiology, American Medical Association, American Society of Head and Neck Radiology, American Society of Neuroradiology, Association of University Radiologists, Radiological Society of North America
Disclosure: Nothing to disclose.
Chief Editor
L Gill Naul, MD Professor and Head, Department of Radiology, Texas A&M University College of Medicine; Chair, Department of Radiology, Baylor Scott and White Healthcare, Central Division
L Gill Naul, MD is a member of the following medical societies: American College of Radiology, American Medical Association, American Roentgen Ray Society, Radiological Society of North America
Disclosure: Nothing to disclose.
Additional Contributors
Barton F Branstetter, IV, MD Professor of Radiology, Otolaryngology, and Biomedical Informatics, University of Pittsburgh School of Medicine; Chief of Neuroradiology, University of Pittsburgh Medical Center
Barton F Branstetter, IV, MD is a member of the following medical societies: American College of Radiology, American Medical Association, American Roentgen Ray Society, American Society of Head and Neck Radiology, American Society of Neuroradiology, Pennsylvania Medical Society, Radiological Society of North America
Disclosure: Nothing to disclose.
Huang M, Patel J, Patel BC. Optic Nerve Glioma. 2020 Jan. [QxMD MEDLINE Link]. [Full Text].
Robert-Boire V, Rosca L, Samson Y, Ospina LH, Perreault S. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma. Pediatr Neurol. 2017 Oct. 75:55-60. [QxMD MEDLINE Link].
Wilhelm H. Primary optic nerve tumours. Curr Opin Neurol. 2009 Feb. 22(1):11-8. [QxMD MEDLINE Link].
Rolston JD, Han SJ, Cotter JA, El-Sayed IH, Aghi MK. Gangliogliomas of the optic pathway. J Clin Neurosci. 2014 Dec. 21 (12):2244-9. [QxMD MEDLINE Link].
Glass LR, Canoll P, Lignelli A, Ligon AH, Kazim M. Optic nerve glioma: case series with review of clinical, radiologic, molecular, and histopathologic characteristics. Ophthal Plast Reconstr Surg. 2014 Sep-Oct. 30 (5):372-6. [QxMD MEDLINE Link].
Messori A, Salvolini U. Hybrid phakomatosis: from initial CT observation to molecular studies. AJNR Am J Neuroradiol. 2004 Aug. 25(7):1297-8.
Park ES, Park JB, Ra YS. Pediatric Glioma at the Optic Pathway and Thalamus. J Korean Neurosurg Soc. 2018 May. 61 (3):352-362. [QxMD MEDLINE Link]. [Full Text].
Rasool N, Odel JG, Kazim M. Optic pathway glioma of childhood. Curr Opin Ophthalmol. 2017 May. 28 (3):289-295. [QxMD MEDLINE Link].
Aoki S, Barkovich AJ, Nishimura K, et al. Neurofibromatosis types 1 and 2: cranial MR findings. Radiology. 1989 Aug. 172(2):527-34. [QxMD MEDLINE Link].
Hendrix LE, Kneeland JB, Haughton VM, et al. MR imaging of optic nerve lesions: value of gadopentetate dimeglumine and fat-suppression technique. AJNR Am J Neuroradiol. 1990 Jul-Aug. 11(4):749-54. [QxMD MEDLINE Link].
Forte R, Cennamo G, Breve MA. Three-Dimensional Ultrasound of Ophthalmic Pathologies. Ophthalmologica. 2009 Jan 31. 223(3):183-187. [QxMD MEDLINE Link].
Walrath JD, Engelbert M, Kazim M. Magnetic resonance imaging evidence of optic nerve glioma progression into and beyond the optic chiasm. Ophthal Plast Reconstr Surg. 2008 Nov-Dec. 24(6):473-5. [QxMD MEDLINE Link].
Buffa A, Vannelli S, Peretta P. [NF1 and gliomas: the importance of the MRI]. Minerva Pediatr. 2008 Apr. 60(2):259-60. [QxMD MEDLINE Link].
Khan SN, Sepahdari AR. Orbital masses: CT and MRI of common vascular lesions, benign tumors, and malignancies. Saudi J Ophthalmol. 2012 Oct. 26(4):373-83. [QxMD MEDLINE Link]. [Full Text].
Menjot de Champfleur N, Leboucq N, Menjot de Champfleur S, Bonafe A. Imaging of the pre-chiasmatic optic nerve. Diagn Interv Imaging. 2013 Oct. 94(10):973-84. [QxMD MEDLINE Link].
Spicer GJ, Kazim M, Glass LR, et al. Accuracy of MRI in defining tumor-free margin in optic nerve glioma surgery. Ophthal Plast Reconstr Surg. 2013 Jul-Aug. 29(4):277-80. [QxMD MEDLINE Link].
Shofty B, Mauda-Havakuk M, Weizman L, Constantini S, Ben-Bashat D, Dvir R, et al. The effect of chemotherapy on optic pathway gliomas and their sub-components: A volumetric MR analysis study. Pediatr Blood Cancer. 2015 Aug. 62 (8):1353-9. [QxMD MEDLINE Link].
Avery RA, Hwang EI, Ishikawa H, Acosta MT, Hutcheson KA, Santos D, et al. Handheld optical coherence tomography during sedation in young children with optic pathway gliomas. JAMA Ophthalmol. 2014 Mar. 132 (3):265-71. [QxMD MEDLINE Link].
Sindhuja A, Indiran V, Santhanam R, Maduraimuthu P. Tram-track-like calcification in adult optic pathway glioma. BJR Case Rep. 2016. 2 (3):20150378. [QxMD MEDLINE Link].
Kornreich L, Blaser S, Schwarz M, et al. Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. AJNR Am J Neuroradiol. 2001 Nov-Dec. 22(10):1963-9. [QxMD MEDLINE Link].
Campen CJ, Gutmann DH. Optic Pathway Gliomas in Neurofibromatosis Type 1. J Child Neurol. 2018 Jan. 33 (1):73-81. [QxMD MEDLINE Link]. [Full Text].